Skip to main content

Articles

Page 1 of 25

  1. Patient stratification is the division of a patient population into distinct subgroups based on the presence or absence of particular disease characteristics. As patient stratification can be used to account f...

    Authors: Carla Abdelnour, Federica Agosta, Marco Bozzali, Bertrand Fougère, Atsushi Iwata, Ramin Nilforooshan, Leonel T. Takada, Félix Viñuela and Martin Traber
    Citation: Alzheimer's Research & Therapy 2022 14:112
  2. Mild cognitive impairment (MCI) is an early stage of cognitive decline which could develop into dementia. An early detection of MCI is a crucial step for timely prevention and intervention. Recent studies have...

    Authors: Natthanan Ruengchaijatuporn, Itthi Chatnuntawech, Surat Teerapittayanon, Sira Sriswasdi, Sirawaj Itthipuripat, Solaphat Hemrungrojn, Prodpran Bunyabukkana, Aisawan Petchlorlian, Sedthapong Chunamchai, Thiparat Chotibut and Chaipat Chunharas
    Citation: Alzheimer's Research & Therapy 2022 14:111
  3. Patients and caregivers express a desire for accurate prognostic information about time to institutionalization and mortality. Previous studies predicting institutionalization and mortality focused on the deme...

    Authors: Arenda Mank, Ingrid S. van Maurik, Judith J. M. Rijnhart, Els D. bakker, Vincent Bouteloup, Lisa Le Scouarnec, Charlotte E. Teunissen, Frederik Barkhof, Philip Scheltens, Johannes Berkhof and Wiesje M. van der Flier
    Citation: Alzheimer's Research & Therapy 2022 14:110
  4. The differentiation of Lewy body dementia from other common dementia types clinically is difficult, with a considerable number of cases only being found post-mortem. Consequently, there is a clear need for ine...

    Authors: Jack L. Jennings, Luis R. Peraza, Mark Baker, Kai Alter, John-Paul Taylor and Roman Bauer
    Citation: Alzheimer's Research & Therapy 2022 14:109
  5. In fewer than 1% of patients, AD is caused by autosomal dominant mutations in either the presenilin 1 (PSEN1), presenilin 2 (PSEN2), or amyloid precursor protein (APP) genes. The full extent of familial AD and fr...

    Authors: Leonel Tadao Takada, Carmen Aláez-Verson, Bhagyashri D. Burgute, Ricardo Nitrini, Ana Luisa Sosa, Raphael Machado Castilhos, Marcia Fagundes Chaves, Erika-Mariana Longoria, Karol Carrillo-Sánchez, Sonia Maria Dozzi Brucki, Luis Leonardo Flores-Lagunes, Carolina Molina, Marcos Jimenez Olivares, Ellen Ziegemeier, Jennifer Petranek, Alison M. Goate…
    Citation: Alzheimer's Research & Therapy 2022 14:108
  6. Early and accurate diagnosis of Alzheimer’s disease (AD) is essential for disease management and therapeutic choices that can delay disease progression. Machine learning (ML) approaches have been extensively u...

    Authors: Vasco Sá Diogo, Hugo Alexandre Ferreira and Diana Prata
    Citation: Alzheimer's Research & Therapy 2022 14:107
  7. This study investigated plasma biomarkers for neuroinflammation associated with Alzheimer’s disease (AD) in subjects with preclinical AD compared to healthy elderly. How these biomarkers behave in patients wit...

    Authors: Samantha Prins, Marieke L. de Kam, Charlotte E. Teunissen and Geert Jan Groeneveld
    Citation: Alzheimer's Research & Therapy 2022 14:106
  8. The ability of 18F-PI-2620 PET to measure the spatial distribution of tau pathology in Alzheimer’s disease (AD) has been demonstrated in previous studies. The objective of this work was to evaluate tau deposition...

    Authors: Santiago Bullich, Andre Mueller, Susan De Santi, Norman Koglin, Stephen Krause, June Kaplow, Michio Kanekiyo, Núria Roé-Vellvé, Audrey Perrotin, Aleksandar Jovalekic, David Scott, Michelle Gee, Andrew Stephens and Michael Irizarry
    Citation: Alzheimer's Research & Therapy 2022 14:105
  9. The S209F variant of Abelson Interactor Protein 3 (ABI3) increases risk for Alzheimer’s disease (AD), but little is known about its function in relation to AD pathogenesis.

    Authors: Kristen R. Ibanez, Karen N. McFarland, Jennifer Phillips, Mariet Allen, Christian B. Lessard, Lillian Zobel, Elsa Gonzalez De La Cruz, Shivani Shah, Quan Vo, Xue Wang, Zachary Quicksall, Daniel Ryu, Cory Funk, Nilüfer Ertekin-Taner, Stefan Prokop, Todd E. Golde…
    Citation: Alzheimer's Research & Therapy 2022 14:104
  10. The deposition of β-amyloid (Aβ) in the brain plays a major role in the pathogenesis of Alzheimer’s disease (AD). Aβ is generated via amyloid precursor protein (APP) cleavage through the amyloidogenic pathway....

    Authors: Yaqi Wang, Yuting Cui, Jing Liu, Qiao Song, Min Cao, Yuli Hou, Xiaomin Zhang and Peichang Wang
    Citation: Alzheimer's Research & Therapy 2022 14:103
  11. Cognitive reserve and resilience are terms used to explain interindividual variability in maintenance of cognitive health in response to adverse factors, such as brain pathology in the context of aging or neur...

    Authors: Jeremy A. Elman, Jacob W. Vogel, Diana I. Bocancea, Rik Ossenkoppele, Anna C. van Loenhoud, Xin M. Tu and William S. Kremen
    Citation: Alzheimer's Research & Therapy 2022 14:102
  12. Neuronal hyperexcitability and inhibitory interneuron dysfunction are frequently observed in preclinical animal models of Alzheimer’s disease (AD). This study investigates whether these microscale abnormalitie...

    Authors: Anne M. van Nifterick, Alida A. Gouw, Ronald E. van Kesteren, Philip Scheltens, Cornelis J. Stam and Willem de Haan
    Citation: Alzheimer's Research & Therapy 2022 14:101
  13. YKL-40 (Chitinase 3-like I) is increased in CSF of Alzheimer’s disease (AD) and frontotemporal lobar degeneration (FTLD) patients and is therefore considered a potential neuroinflammatory biomarker. Whether ch...

    Authors: Yanaika S. Hok-A-Hin, Jeroen J. M. Hoozemans, William T. Hu, Dorine Wouters, Jennifer C. Howell, Alberto Rábano, Wiesje M. van der Flier, Yolande A. L. Pijnenburg, Charlotte E. Teunissen and Marta del Campo
    Citation: Alzheimer's Research & Therapy 2022 14:100
  14. Decreased visual acuity (VA) is reported to be a risk factor for dementia. However, the association between VA and cortical thickness has not been established. We investigated the association between VA and co...

    Authors: Gyule Han, Ji Sun Kim, Yu Hyun Park, Sung Hoon Kang, Hang-Rai Kim, Song Hwangbo, Tae-Young Chung, Hee Young Shin, Duk L. Na, Sang Won Seo, Dong Hui Lim and Hee Jin Kim
    Citation: Alzheimer's Research & Therapy 2022 14:99
  15. People with subjective cognitive decline (SCD) report cognitive deterioration. However, their performance in neuropsychological evaluation falls within the normal range. The present study aims to analyse wheth...

    Authors: Pablo Arrondo, Óscar Elía-Zudaire, Gloria Martí-Andrés, María A. Fernández-Seara and Mario Riverol
    Citation: Alzheimer's Research & Therapy 2022 14:98
  16. The prevalence of dementia is expected to increase dramatically. Due to a lack of pharmacological treatment options for people with dementia, non-pharmacological treatments such as exercise programs have been ...

    Authors: Kathrin Steichele, Anne Keefer, Nikolas Dietzel, Elmar Graessel, Hans-Ulrich Prokosch and Peter L. Kolominsky-Rabas
    Citation: Alzheimer's Research & Therapy 2022 14:97
  17. Isolated subjective cognitive impairment (SCI) and mild cognitive impairment (MCI) are the prodromal phases of dementia with Lewy bodies (DLB). MEMENTO is a nationwide study of patients with SCI and MCI with c...

    Authors: Frederic Blanc, Vincent Bouteloup, Claire Paquet, Marie Chupin, Florence Pasquier, Audrey Gabelle, Mathieu Ceccaldi, Paulo Loureiro de Sousa, Pierre Krolak-Salmon, Renaud David, Clara Fischer, Jean-François Dartigues, David Wallon, Olivier Moreaud, Mathilde Sauvée, Catherine Belin…
    Citation: Alzheimer's Research & Therapy 2022 14:96
  18. We previously identified four Alzheimer’s disease (AD) subgroups with increasingly higher cerebrospinal fluid (CSF) levels of tau phosphorylated at threonine 181 (p-tau). These subgroups included individuals a...

    Authors: Kirsten E. J. Wesenhagen, Betty M. Tijms, Lynn Boonkamp, Patty L. Hoede, Julie Goossens, Nele Dewit, Philip Scheltens, Eugeen Vanmechelen, Pieter Jelle Visser and Charlotte E. Teunissen
    Citation: Alzheimer's Research & Therapy 2022 14:95
  19. Multidomain trials to prevent dementia by simultaneously targeting multiple risk factors with non-pharmacological lifestyle interventions show promise. Designing trials to evaluate the efficacy of individual i...

    Authors: Manuel Montero-Odasso, G Y Zou, Nellie Kamkar, Howard H. Feldman, Sylvie Belleville, Howard Chertkow, Haakon B Nygaard, Surim Son and Mark Speechley
    Citation: Alzheimer's Research & Therapy 2022 14:94
  20. About 40–50% of patients with amnestic mild cognitive impairment (MCI) are found to have no significant Alzheimer’s pathology based on amyloid PET positivity. Notably, conversion to dementia in this population...

    Authors: Hyung-Ji Kim, Jungsu S. Oh, Jae-Sung Lim, Sunju Lee, Sungyang Jo, E-Nae Chung, Woo-Hyun Shim, Minyoung Oh, Jae Seung Kim, Jee Hoon Roh and Jae-Hong Lee
    Citation: Alzheimer's Research & Therapy 2022 14:93
  21. Alzheimer’s disease (AD) pathology is associated with complex interactions among multiple factors, involving an intertwined network of various signaling pathways. The polypharmacological approach is an emergin...

    Authors: Byung Woo Kang, Fred Kim, Joon-Yong Cho, SangYun Kim, Jinseol Rhee and Jai Jun Choung
    Citation: Alzheimer's Research & Therapy 2022 14:92
  22. Safety concerns against the use of proton pump inhibitors (PPIs) based on the risk of dementia, especially Alzheimer’s disease (AD), remain controversial. Here, we investigated the likelihood of AD depending o...

    Authors: Hyo Geun Choi, Joo-Hee Kim, Ji Hee Kim, Eun Soo Kim, Ha Young Park, Kyueng-Whan Min and Mi Jung Kwon
    Citation: Alzheimer's Research & Therapy 2022 14:91
  23. To elucidate the clinical and ancillary features of genetic prion diseases (gPrDs) presenting with frontotemporal dementia (FTD) to aid early identification.

    Authors: Zhongyun Chen, Min Chu, Li Liu, Jing Zhang, Yu Kong, Kexin Xie, Yue Cui, Hong Ye, Junjie Li, Lin Wang and Liyong Wu
    Citation: Alzheimer's Research & Therapy 2022 14:90
  24. To promote the development of effective therapies, there is an important need to characterize the full spectrum of neuropathological changes associated with Alzheimer’s disease. In line with this need, this st...

    Authors: Dorothee Schoemaker, Maria Clara Zanon Zotin, Kewei Chen, Kay C. Igwe, Clara Vila-Castelar, Jairo Martinez, Ana Baena, Joshua T. Fox-Fuller, Francisco Lopera, Eric M. Reiman, Adam M. Brickman and Yakeel T. Quiroz
    Citation: Alzheimer's Research & Therapy 2022 14:89
  25. The apolipoprotein E (APOE) ε4 allele confers the strongest risk for late-onset Alzheimer’s disease (AD) besides age itself, but the mechanisms underlying this risk are debated. One hypothesis supported by eviden...

    Authors: Noah R. Johnson, Athena C.-J. Wang, Christina Coughlan, Stefan Sillau, Esteban Lucero, Lisa Viltz, Neil Markham, Cody Allen, A. Ranjitha Dhanasekaran, Heidi J. Chial and Huntington Potter
    Citation: Alzheimer's Research & Therapy 2022 14:88
  26. Inducing brain ATP-binding cassette 1 (ABCA1) activity in Alzheimer’s disease (AD) mouse models is associated with improvement in AD pathology. The purpose of this study was to investigate the effects of the A...

    Authors: Sasan D. Noveir, Bilal E. Kerman, Haotian Xian, Cristiana Meuret, Sabrina Smadi, Ashley E. Martinez, Johannes Johansson, Henrik Zetterberg, Bryan A. Parks, Zsuzsanna Kuklenyik, Wendy J. Mack, Jan O. Johansson and Hussein N. Yassine
    Citation: Alzheimer's Research & Therapy 2022 14:87
  27. Clinicians, researchers, and patients alike would greatly benefit from more accessible and inexpensive biomarkers for neural β-amyloid (Aβ). We aimed to assess the performance of fully automated plasma Aβ immu...

    Authors: Kazuto Yamashita, Masahiro Miura, Shunsuke Watanabe, Kengo Ishiki, Yuji Arimatsu, Junko Kawahira, Toshiko Kubo, Katsutaka Sasaki, Takayuki Arai, Kei Hagino, Yasuhiro Irino, Kota Nagai, David Verbel, Akihiko Koyama, Shobha Dhadda, Hayato Niiro…
    Citation: Alzheimer's Research & Therapy 2022 14:86
  28. We developed the Alzheimer’s Biomarker Survey to assess willingness to enroll in biomarker studies that disclose results and anticipated reactions to an elevated biomarker result.

    Authors: Lindsay R. Clark, Claire M. Erickson, Erin M. Jonaitis, Yue Ma, Nathaniel A. Chin, Kristin Basche, Frederick B. Ketchum and Carey E. Gleason
    Citation: Alzheimer's Research & Therapy 2022 14:85
  29. Low-intensity light can decelerate neurodegenerative disease progression and reduce amyloid β (Aβ) levels in the cortex, though the cellular and molecular mechanisms by which photobiomodulation (PBM) protects ...

    Authors: Yurii V. Stepanov, Iuliia Golovynska, Renlong Zhang, Sergii Golovynskyi, Liudmyla I. Stepanova, Oleksandr Gorbach, Taisa Dovbynchuk, Liudmyla V. Garmanchuk, Tymish Y. Ohulchanskyy and Junle Qu
    Citation: Alzheimer's Research & Therapy 2022 14:84
  30. The literature has shown depression to be associated with an increased risk of dementia. In addition, hormone therapy can be a responsive treatment option for a certain type of depression. In this study, we ex...

    Authors: Hyewon Kim, Juhwan Yoo, Kyungdo Han, Dong-Yun Lee, Maurizio Fava, David Mischoulon and Hong Jin Jeon
    Citation: Alzheimer's Research & Therapy 2022 14:83
  31. Authors: Colin Groot, Claudia Cicognola, Divya Bali, Gallen Triana-Baltzer, Jeffrey L. Dage, Michael J. Pontecorvo, Hartmuth C. Kolb, Rik Ossenkoppele, Shorena Janelidze and Oskar Hansson
    Citation: Alzheimer's Research & Therapy 2022 14:82

    The original article was published in Alzheimer's Research & Therapy 2022 14:67

  32. Authors: Miranka Wirth, Claudia Schwarz, Gloria Benson, Nora Horn, Ralph Buchert, Catharina Lange, Theresa Köbe, Stefan Hetzer, Marta Maglione, Eva Michael, Stefanie Märschenz, Knut Mai, Ute Kopp, Dietmar Schmitz, Ulrike Grittner, Stephan J. Sigrist…
    Citation: Alzheimer's Research & Therapy 2022 14:81

    The original article was published in Alzheimer's Research & Therapy 2019 11:36

  33. Validation of new biomarkers of Alzheimer disease (AD) is crucial for the successful development and implementation of treatment strategies. Additional to traditional AT(N) biomarkers, neuroinflammation biomar...

    Authors: Luka Rejc, Vanessa Gómez-Vallejo, Ana Joya, Gemma Arsequell, Ander Egimendia, Pilar Castellnou, Xabier Ríos-Anglada, Unai Cossío, Zuriñe Baz, Leyre Iglesias, Estibaliz Capetillo-Zarate, Pedro Ramos-Cabrer, Abraham Martin and Jordi Llop
    Citation: Alzheimer's Research & Therapy 2022 14:80
  34. Two main genetic risks for sporadic Alzheimer’s disease (AD) are a family history and ɛ4 allele of apolipoprotein E. The brain and retina are part of the central nervous system and share pathophysiological mec...

    Authors: Inés López-Cuenca, Alberto Marcos-Dolado, Miguel Yus-Fuertes, Elena Salobrar-García, Lorena Elvira-Hurtado, José A. Fernández-Albarral, Juan J. Salazar, Ana I. Ramírez, Lidia Sánchez-Puebla, Manuel Enrique Fuentes-Ferrer, Ana Barabash, Federico Ramírez-Toraño, Lidia Gil-Martínez, Juan Arrazola-García, Pedro Gil, Rosa de Hoz…
    Citation: Alzheimer's Research & Therapy 2022 14:79
  35. Synaptic dysfunction and degeneration are central to Alzheimer’s disease (AD) and have been found to correlate strongly with cognitive decline. Thus, studying cerebrospinal fluid (CSF) biomarkers reflecting sy...

    Authors: Johanna Nilsson, Nicholas J. Ashton, Andrea L. Benedet, Laia Montoliu-Gaya, Johan Gobom, Tharick A. Pascoal, Mira Chamoun, Erik Portelius, Andreas Jeromin, Muriel Mendes, Henrik Zetterberg, Pedro Rosa-Neto, Ann Brinkmalm and Kaj Blennow
    Citation: Alzheimer's Research & Therapy 2022 14:78
  36. Many families with clinical early-onset Alzheimer’s disease (EOAD) remain genetically unexplained. A combination of genetic factors is not standardly investigated. In addition to monogenic causes, we evaluated...

    Authors: Merel O. Mol, Sven J. van der Lee, Marc Hulsman, Yolande A. L. Pijnenburg, Phillip Scheltens, Harro Seelaar, John C. van Swieten, Laura Donker Kaat, Henne Holstege and Jeroen G. J. van Rooij
    Citation: Alzheimer's Research & Therapy 2022 14:77
  37. This article has been retracted. Please see the Retraction Notice for more detail: https://0-doi-org.brum.beds.ac.uk/10.1186/s13195-017-0280-8.

    Authors: Hoau-Yan Wang, Caryn Trocmé-Thibierge, Andres Stucky, Sanket M. Shah, Jessica Kvasic, Amber Khan, Philippe Morain, Isabelle Guignot, Eva Bouguen, Karine Deschet, Maria Pueyo, Elisabeth Mocaer, Pierre-Jean Ousset, Bruno Vellas and Vera Kiyasova
    Citation: Alzheimer's Research & Therapy 2022 14:76
  38. No population-based cohort study investigated a potential inverse association between long-term low-dose acetylsalicylic acid (ASA) use and all-cause dementia and its two most common sub-types Alzheimer’s dise...

    Authors: Thi Ngoc Mai Nguyen, Li-Ju Chen, Kira Trares, Hannah Stocker, Bernd Holleczek, Konrad Beyreuther, Hermann Brenner and Ben Schöttker
    Citation: Alzheimer's Research & Therapy 2022 14:75
  39. This study sought to explore the association between Life’s Simple 7 (LS7) and cerebrospinal fluid (CSF) Alzheimer’s disease (AD) pathological biomarkers in the cognitively normal northern Chinese population.

    Authors: Yong-Li Zhao, Ya-Nan Ou, Ya-Hui Ma, Yu-Yuan Huang, Yan-Lin Bi, Lan Tan and Jin-Tai Yu
    Citation: Alzheimer's Research & Therapy 2022 14:74
  40. This study assesses the relationships between dynamic functional network connectivity (DFNC) and dementia risk.

    Authors: Sophie Dautricourt, Julie Gonneaud, Brigitte Landeau, Vince D. Calhoun, Robin de Flores, Géraldine Poisnel, Salma Bougacha, Valentin Ourry, Edelweiss Touron, Elizabeth Kuhn, Harriet Demintz-King, Natalie L. Marchant, Denis Vivien, Vincent de la Sayette, Antoine Lutz and Gaël Chételat
    Citation: Alzheimer's Research & Therapy 2022 14:72
  41. Synaptic dysfunction is an early core feature of Alzheimer’s disease (AD), closely associated with cognitive symptoms. Neuregulin 1 (NRG1) is a growth and differentiation factor with a key role in the developm...

    Authors: Agathe Vrillon, François Mouton-Liger, Matthieu Martinet, Emmanuel Cognat, Claire Hourregue, Julien Dumurgier, Elodie Bouaziz-Amar, Ann Brinkmalm, Kaj Blennow, Henrik Zetterberg, Jacques Hugon and Claire Paquet
    Citation: Alzheimer's Research & Therapy 2022 14:71
  42. Authors: Chad J. Swanson, Yong Zhang, Shobha Dhadda, Jinping Wang, June Kaplow, Robert Y. K. Lai, Lars Lannfelt, Heather Bradley, Martin Rabe, Akihiko Koyama, Larisa Reyderman, Donald A. Berry, Scott Berry, Robert Gordon, Lynn D. Kramer and Jeffrey L. Cummings
    Citation: Alzheimer's Research & Therapy 2022 14:70

    The original article was published in Alzheimer's Research & Therapy 2021 13:80

  43. Currently, Alzheimer’s disease (AD) cohort datasets are difficult to find and lack across-cohort interoperability, and the actual content of publicly available datasets often only becomes clear to third-party ...

    Authors: Yasamin Salimi, Daniel Domingo-Fernández, Carlos Bobis-Álvarez, Martin Hofmann-Apitius and Colin Birkenbihl
    Citation: Alzheimer's Research & Therapy 2022 14:69
  44. This work aimed to investigate the potential pathways involved in the association between social and lifestyle factors, biomarkers of Alzheimer’s disease and related dementia (ADRD), and cognition.

    Authors: Leslie Grasset, Cécile Proust-Lima, Jean-François Mangin, Marie-Odile Habert, Bruno Dubois, Claire Paquet, Olivier Hanon, Audrey Gabelle, Mathieu Ceccaldi, Cédric Annweiler, Renaud David, Therese Jonveaux, Catherine Belin, Adrien Julian, Isabelle Rouch-Leroyer, Jérémie Pariente…
    Citation: Alzheimer's Research & Therapy 2022 14:68
  45. Recent advances in disease-modifying treatments highlight the need for accurately identifying individuals in early Alzheimer’s disease (AD) stages and for monitoring of treatment effects. Plasma measurements o...

    Authors: Colin Groot, Claudia Cicognola, Divya Bali, Gallen Triana-Baltzer, Jeffrey L. Dage, Michael J. Pontecorvo, Hartmuth C. Kolb, Rik Ossenkoppele, Shorena Janelidze and Oskar Hansson
    Citation: Alzheimer's Research & Therapy 2022 14:67

    The Correction to this article has been published in Alzheimer's Research & Therapy 2022 14:82

  46. Blood biomarkers that can be used for preclinical Alzheimer’s disease (AD) diagnosis would enable trial enrollment at a time when the disease is potentially reversible. Here, we investigated plasma neuronal-de...

    Authors: Tao-Ran Li, Yun-Xia Yao, Xue-Yan Jiang, Qiu-Yue Dong, Xian-Feng Yu, Ting Wang, Yan-Ning Cai and Ying Han
    Citation: Alzheimer's Research & Therapy 2022 14:66
  47. Blood phosphorylated tau (p-tau) forms are promising Alzheimer’s disease (AD) biomarkers, but validation in matrices other than ethylenediaminetetraacetic acid (EDTA) plasma is limited. Firstly, we assessed th...

    Authors: Przemysław R. Kac, Fernando Gonzalez-Ortiz, Joel Simrén, Nele Dewit, Eugeen Vanmechelen, Henrik Zetterberg, Kaj Blennow, Nicholas J. Ashton and Thomas K. Karikari
    Citation: Alzheimer's Research & Therapy 2022 14:65
  48. The primary progressive aphasia (PPA) diagnosis trajectory is debated, as several changes in diagnosis occur during PPA course, due to phenotype evolution from isolated language alterations to global cognitive...

    Authors: A. Mouton, A. Plonka, R. Fabre, T. M. Tran, P. Robert, J. Macoir, V. Manera and A. Gros
    Citation: Alzheimer's Research & Therapy 2022 14:64
  49. The combined effects of increased life expectancy and the considerable number of persons reaching old age will magnify the dementia epidemic in the USA. Demonstration that subclinical atherosclerosis precedes ...

    Authors: Felice Lin, Judy Pa, Roksana Karim, Howard N. Hodis, S. Duke Han, Victor W. Henderson, Jan A. St. John and Wendy J. Mack
    Citation: Alzheimer's Research & Therapy 2022 14:63